Use of a Biomarker in Exposure–Response Analysis to Support Dose Selection for Fingolimod
Fingolimod 0.5 mg q.d. (once daily) has been approved for the treatment of patients with relapsing and remitting forms of multiple sclerosis (RRMS). Fingolimod at two doses (0.5 and 1.25 mg) showed superior effectiveness in the frequency of relapse with little difference between the two dose groups....
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828008/ |